Metformin interference with the ERK-NFkB axis has been shown to attenuate the resistance of non-small cell lung cancer (NSCLC) cell lines to both gefitinib and a third-gen epidermal growth factor receptor (EGFR) tyrosine-kinase-inhibitors (TKI) [185,186]. The gene discussed is NFKB1; the disease is non-small cell lung carcinoma.